Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
A team of investigators sought to determine the influence of infliximab on gut bacterial and fungal composition in patients with inflammatory bowel disease.
As Crohn disease perianal fistulas often do not respond to available treatments, researchers developed a patient-derived quality-of-life tool to evaluate the impact of the condition on patients.
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
Interview study identified categories in which improved psychological support services are needed for these patients.
Lower socioeconomic status is associated with worse outcomes for inflammatory bowel disease.
Investigators assessed the Controlling Nutritional Status’ (CONUT’s) efficacy in predicting postoperative complications in patients with Crohn disease.
Although the emergence of COVID-19 initially called the continuation of inflammatory bowel disease (IBD) therapy into question, treatment has proceeded — albeit with added considerations.
Investigators assessed whether depression, adjusted for preexisting gastrointestinal symptoms, is associated with subsequent inflammatory bowel disease.
Investigators used a machine learning strategy to seek out plasma protein biomarkers for stricturing and penetrating complications.
Investigators analyzed the surgical risk for ulcerative colitis and Crohn disease in contemporary, population-based inception cohorts vs 20th century cohorts.
The investigators used a commercial database containing electronic health record data from 26 major United States healthcare systems to assess the effect of biologics on surgery rates in the IBD setting.
The NIH-led trial will assess 3 drugs: infliximab, a tumor necrosis factor blocker, abatacept, a selective T cell costimulation modulator, and cenicriviroc, an investigational immunomodulator that blocks 2 chemokine receptors, CCR2 and CCR5.
Managing for elderly patients with inflammatory bowel disease involves unique challenges in both diagnosis and therapeutic decision making.
The goal of this study was to describe changes in the microbiota, metabolome, and protease activity related to mucosal healing in established pediatric Crohn disease.
Therapies for the treatment of inflammatory bowel disease may have a potential use in patients with COVID-19.
Alimentary Pharmacology and Therapeutics reports on the final results from the GEMINI long-term safety study on vedolizumab, a gut-selective α4 β7 integrin antibody approved for moderately to severely active ulcerative colitis and Crohn disease.
An analysis of 3 large prospective cohorts examined the association between dietary patterns with high inflammatory potential and increased risks for Crohn disease and ulcerative colitis.
Researchers analyzed independent risk factors for short bowel syndrome in patients with Crohn disease in an effort to develop preventive strategies.
A team of investigators conducted a systematic review and meta-analysis to assess the risk of extraintestinal cancer in patients with inflammatory bowel disease.